Serum estradiol above the postmenopausal level after chemotherapy-induced amenorrhea in breast cancer patients

Therapy

Volumn 3, Issue 5, 2006, Pages 609-612

  Braverman, Albert S ^a   Sawhney, Harindar ^a   Tendler, Aron ^a   Patel, Nilesh ^a   Rao, Sujatha ^a   El Tamer, Mahmoud ^b   Kamenova, Boriana ^a   Weedon, Jeremy ^c  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b Department of Orthopaedic Surgery   (United States)

^c Downstate Health Sciences University   (United States)

Author keywords

Breast cancer; Chemotherapy; Estrogen; Menopause; Ovarian function

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRADIOL; ESTROGEN; FLUOROURACIL; FOLLITROPIN; LUTEINIZING HORMONE; METHOTREXATE; PACLITAXEL;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INDUCED DISEASE; ESTRADIOL BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; STATISTICAL SIGNIFICANCE;

EID: 33750049947     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.3.5.609     Document Type: Article

References (18)

1. Papendorp JT, Schatz RW, Soto AM, Sonnenschein C. On the role of 17α-estradiol and 17β-estradiol in the proliferation of MCF7 and T47D-A11 human breast tumor cells. J. Cell. Physiol. 125, 591-595 (1985).
2. Lippman ME, Osborne CK, Knazek R et al. In vitro model systems for the study of hormone-dependent human breast cancer. N. Engl. J. Med. 296, 154-159 (1977).
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic of immune therapy. Lancet 339, 2-15 (1992).
4. Goodwin PJ, Ennis M, Pritchard KI et al. Risk of menopause during the first year after breast cancer diagnosis. J. Clin. Oncol. 17, 2365-2370 (1999).
5. Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management. Drug Safety 28, 401-416 (2005).
6. Vanhuyse M, Fournier C, Bonneterre J. Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann. Oncol. 16, 1283-1288 (2005).
7. Parulekar WR, Day AG, Ottaway JA et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer. J. Clin. Oncol. 23, 6002-6008 (2005).
8. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol. 20, 4628-4635 (2002).
9. Jakesz R, Hausmaninger H, Kubista E et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J. Clin. Oncol. 20, 4621-4627 (2002).
10. Strasser-Wipl K, Goss PE. Advances in adjuvant hormonal therapy for post-menopausal women. J. Clin. Oncol. 23, 1751-1759 (2005).
11. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant endocrine therapy for pre-menopausal women with early breast cancer. J. Clin. Oncol. 23, 1735-1750 (2005).
12. Burger HG. The endocrinology of menopause. Maturitas 23, 129-136 (1996).
13. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104, 1575-1579 (2005).
14. Davis AL, Klitus M, Mintzer DM. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin. Breast Cancer 6, 421-424 (2005).
15. Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition. Clin. Endocrinol. 14, 245-255 (1981).
16. Rannevik G, Caristrom K, Jeppsson S et al. A prospective long-term study in women from pre-menopause to post-menopause. Maturitas 8, 297-307 (1986).
17. Smith IE, Dowsett M, Yap YS et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J. Clin. Oncol. 24, 2444-2447 (2006).
18. Braverman AS, Sawhney H, Tendler A, Patel N, Rao S. Premenopausal serum estradiol levels may persist after chemotherapy-induced amenorrhea in breast cancer. Proc. Am. Soc. Clin. Oncol. 21, 42a (2002) (Abstract 164).